Stay updated with breaking news from Chemo Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAINT LAURENT, Quebec, April 05, 2024 -- IntelGenx Corp. today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC , has received a Complete Response...
Operator: Greetings. Welcome to IntelGenx’s Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
SAINT LAURENT, Quebec, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the 'Company' or 'IntelGenx') toda...
SAINT LAURENT, Quebec, Sept. 19, 2023 -- IntelGenx Corp. today provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application has been filed with the...
BALTIMORE — Patients with heavy menstrual bleeding who received the levonorgestrel 52 mg intrauterine device experienced significant and rapid decreases in uterine bleeding after placement, a researcher reported here.Blood loss was reduced by more than 90% over 6 months after placement of the Liletta levonorgestrel-releasing intrauterine system (AbbVie/Medicines360) compared with baseline